Literature DB >> 31020856

New Frontiers of Corneal Gene Therapy.

Enzo Di Iorio1, Vanessa Barbaro2, Gualtiero Alvisi1, Marta Trevisan1, Stefano Ferrari2, Giulia Masi1, Patrizia Nespeca1, Hanieh Ghassabian1, Diego Ponzin2, Giorgio Palù1.   

Abstract

Corneal diseases are among the most prevalent causes of blindness worldwide. The transparency and clarity of the cornea are guaranteed by a delicate physiological, anatomic, and functional balance. For this reason, all the disorders, including those of genetic origin, that compromise this state of harmony can lead to opacity and eventually vision loss. Many corneal disorders have a genetic etiology, and some are associated with rather rare and complex syndromes. Conventional treatments, such as corneal transplantation, are often ineffective, and to date, many of these disorders are still incurable. Gene therapy carries the promise of being a potential cure for many of these diseases, with solutions and strategies that did not seem possible until a few years ago. With its potential to treat genetic disease by means of deletion, replacement, or editing of a defective gene, the challenge can also be extended to corneal disorders in order to achieve long-term, if not definitive, relief. The aim of this paper is to review the state of the art of the different gene therapy approaches as potential treatments for corneal diseases and the future perspectives for the development of personalized gene-based medicine.

Entities:  

Keywords:  corneal diseases; corneal neovascularization; corneal transplantation; gene therapy; non-viral vectors; viral vectors

Mesh:

Year:  2019        PMID: 31020856     DOI: 10.1089/hum.2019.026

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  8 in total

1.  Notch1 signaling in keratocytes maintains corneal transparency by suppressing VEGF expression.

Authors:  Soma Biswas; Md Shafiquzzaman; Guo Yu; Ping Li; Qian Yu; Peiquan Zhao; Baojie Li; Jing Li
Journal:  Stem Cell Reports       Date:  2022-05-26       Impact factor: 7.294

Review 2.  Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses.

Authors:  Hashem H Ghoraba; Amir Akhavanrezayat; Irmak Karaca; Negin Yavari; Sherin Lajevardi; Jaclyn Hwang; Jonathan Regenold; Wataru Matsumiya; Brandon Pham; Moosa Zaidi; Azadeh Mobasserian; Anthony Toan DongChau; Christopher Or; Cigdem Yasar; Kapil Mishra; Diana Do; Quan Dong Nguyen
Journal:  Clin Ophthalmol       Date:  2022-06-03

3.  Novel nanopolymer RNA therapeutics normalize human diabetic corneal wound healing and epithelial stem cells.

Authors:  Andrei A Kramerov; Ruchi Shah; Hui Ding; Eggehard Holler; Sue Turjman; Yaron S Rabinowitz; Sean Ghiam; Ezra Maguen; Clive N Svendsen; Mehrnoosh Saghizadeh; Julia Y Ljubimova; Alexander V Ljubimov
Journal:  Nanomedicine       Date:  2020-11-10       Impact factor: 5.307

Review 4.  Gene Therapy in the Anterior Eye Segment.

Authors:  Cynthia Amador; Ruchi Shah; Sean Ghiam; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Curr Gene Ther       Date:  2022       Impact factor: 4.391

Review 5.  Ocular Drug Delivery: Advancements and Innovations.

Authors:  Bo Tian; Evan Bilsbury; Sean Doherty; Sean Teebagy; Emma Wood; Wenqi Su; Guangping Gao; Haijiang Lin
Journal:  Pharmaceutics       Date:  2022-09-13       Impact factor: 6.525

Review 6.  Novel insights into gene therapy in the cornea.

Authors:  Rajiv R Mohan; Lynn M Martin; Nishant R Sinha
Journal:  Exp Eye Res       Date:  2020-11-16       Impact factor: 3.770

7.  Therapeutic Potential of Extracellular Vesicles for the Treatment of Corneal Injuries and Scars.

Authors:  Sophie X Deng; Aurelie Dos Santos; Serina Gee
Journal:  Transl Vis Sci Technol       Date:  2020-11-02       Impact factor: 3.283

8.  Human MiniPromoters for ocular-rAAV expression in ON bipolar, cone, corneal, endothelial, Müller glial, and PAX6 cells.

Authors:  Andrea J Korecki; Jorge L Cueva-Vargas; Oriol Fornes; Jessica Agostinone; Rachelle A Farkas; Jack W Hickmott; Siu Ling Lam; Anthony Mathelier; Michelle Zhou; Wyeth W Wasserman; Adriana Di Polo; Elizabeth M Simpson
Journal:  Gene Ther       Date:  2021-02-02       Impact factor: 5.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.